Edward Doo

10.9k total citations · 5 hit papers
42 papers, 6.7k citations indexed

About

Edward Doo is a scholar working on Hepatology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Edward Doo has authored 42 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hepatology, 33 papers in Epidemiology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Edward Doo's work include Liver Disease Diagnosis and Treatment (23 papers), Hepatitis B Virus Studies (22 papers) and Hepatitis C virus research (21 papers). Edward Doo is often cited by papers focused on Liver Disease Diagnosis and Treatment (23 papers), Hepatitis B Virus Studies (22 papers) and Hepatitis C virus research (21 papers). Edward Doo collaborates with scholars based in United States, Malaysia and Chile. Edward Doo's co-authors include Jay H. Hoofnagle, David E. Kleiner, Marc G. Ghany, T. Jake Liang, Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal, Mark L. Van Natta, Kris V. Kowdley and James Tonascia and has published in prestigious journals such as The Lancet, Gastroenterology and Hepatology.

In The Last Decade

Edward Doo

42 papers receiving 6.5k citations

Hit Papers

Farnesoid X nuclear receptor ligand obeticholic... 2004 2026 2011 2018 2014 2004 2008 2018 2018 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
    2014 1.7k citations Brent A. Neuschwander‐Tetri, Rohit Loomba et al. The Lancet profile →
  2. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
    2004 587 citations Kittichai Promrat, Glen Lutchman et al. Hepatology profile →
  3. Acute liver failure
    2008 520 citations William M. Lee, Robert H. Squires et al. Hepatology profile →
  4. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
    2018 452 citations Mohammad Shadab Siddiqui, Raj Vuppalanchi et al. profile →
  5. Biliary Atresia: Clinical and Research Challenges for the Twenty‐First Century
    2018 218 citations Jay H. Hoofnagle, Edward Doo et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward Doo United States 26 5.2k 3.7k 1.3k 1.2k 868 42 6.7k
Marcello Persico Italy 41 4.3k 0.8× 3.3k 0.9× 987 0.8× 803 0.7× 716 0.8× 204 6.5k
Bilal Hameed United States 24 4.1k 0.8× 2.5k 0.7× 1.3k 1.0× 1.2k 1.1× 857 1.0× 70 5.7k
Hari S. Conjeevaram United States 36 7.8k 1.5× 6.9k 1.9× 942 0.7× 1.0k 0.9× 733 0.8× 84 9.7k
Lawrence Serfaty France 43 6.5k 1.2× 5.3k 1.4× 1.1k 0.9× 1.3k 1.1× 654 0.8× 161 7.8k
Norberto C. Chávez‐Tapia Mexico 36 2.9k 0.5× 1.7k 0.5× 912 0.7× 1.2k 1.0× 703 0.8× 194 4.7k
Yasuji Arase Japan 52 8.7k 1.7× 9.1k 2.4× 1.1k 0.8× 726 0.6× 878 1.0× 394 11.6k
Patrick Hillon France 37 3.0k 0.6× 2.7k 0.7× 557 0.4× 1.2k 1.0× 568 0.7× 137 5.5k
Andreas Geier Germany 41 3.5k 0.7× 2.4k 0.7× 849 0.7× 1.8k 1.5× 1.4k 1.6× 209 6.7k
Naga Chalasani United States 28 3.3k 0.6× 2.1k 0.6× 1.0k 0.8× 1.2k 1.0× 731 0.8× 69 5.1k
Katsutoshi Tokushige Japan 39 4.3k 0.8× 2.7k 0.7× 1.3k 1.0× 881 0.8× 851 1.0× 204 5.6k

Countries citing papers authored by Edward Doo

Since Specialization
Citations

This map shows the geographic impact of Edward Doo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Doo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Doo more than expected).

Fields of papers citing papers by Edward Doo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Doo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Doo. The network helps show where Edward Doo may publish in the future.

Co-authorship network of co-authors of Edward Doo

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Doo. A scholar is included among the top collaborators of Edward Doo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Doo. Edward Doo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gara, Naveen, Michele Tana, Sungyoung Auh, et al.. (2021). Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response. Hepatology Communications. 5(11). 1888–1900. 4 indexed citations
2.
Gawrieh, Samer, Laura Wilson, Oscar W. Cummings, et al.. (2019). Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. The American Journal of Gastroenterology. 114(10). 1626–1635. 73 indexed citations
3.
Middleton, Michael S., Mark L. Van Natta, Elhamy Heba, et al.. (2017). Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 67(3). 858–872. 114 indexed citations
4.
Vuppalanchi, Raj, Mohammad Shadab Siddiqui, Mark L. Van Natta, et al.. (2017). Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 67(1). 134–144. 188 indexed citations
5.
Neuschwander‐Tetri, Brent A., Rohit Loomba, Arun J. Sanyal, et al.. (2014). Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet. 385(9972). 956–965. 1735 indexed citations breakdown →
6.
Noureddin, Mazen, Katherine P. Yates, Ivana A. Vaughn, et al.. (2013). Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 58(5). 1644–1654. 145 indexed citations
7.
Schrieber, Sarah J., Roy L. Hawke, Zhiming Wen, et al.. (2011). Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C. Drug Metabolism and Disposition. 39(12). 2182–2190. 47 indexed citations
8.
Rotman, Yaron, Brian B. Borg, Alejandro Soza, et al.. (2010). Low‐ and standard‐dose peginterferon alfa‐2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. Alimentary Pharmacology & Therapeutics. 31(9). 1018–1027. 7 indexed citations
9.
Doo, Edward & Marc G. Ghany. (2010). Hepatitis B Virology for Clinicians. Clinics in Liver Disease. 14(3). 397–408. 17 indexed citations
10.
Doo, Edward & Jay H. Hoofnagle. (2009). The hepatitis B research network # †. Hepatology. 49(Suppl. 5). S196–S197. 1 indexed citations
11.
Lee, William M., Robert H. Squires, Scott L. Nyberg, Edward Doo, & Jay H. Hoofnagle. (2008). Acute liver failure. Hepatology. 47(4). 1401–1415. 520 indexed citations breakdown →
12.
Hoofnagle, Jay H., Edward Doo, T. Jake Liang, Russell Fleischer, & Anna S. Lok. (2007). Management of hepatitis B. Hepatology. 45(4). 1056–1075. 471 indexed citations
13.
LaRusso, Nicholas F., Benjamin L. Shneider, Dennis D. Black, et al.. (2006). Primary sclerosing cholangitis: Summary of a workshop. Hepatology. 44(3). 746–764. 166 indexed citations
14.
Promrat, Kittichai, Glen Lutchman, Gabriel I. Uwaifo, et al.. (2004). A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡. Hepatology. 39(1). 188–196. 587 indexed citations breakdown →
15.
Lau, Daryl, Hongxia Ma, Stanley M. Lemon, et al.. (2003). A rapid immunochromatographic assay for hepatitis B virus screening. Journal of Viral Hepatitis. 10(4). 331–334. 29 indexed citations
16.
Hoofnagle, Jay H., Marc G. Ghany, David E. Kleiner, et al.. (2003). Maintenance Therapy With Ribavirin in Patients With Chronic Hepatitis C Who Fail to Respond to Combination Therapy With Interferon Alfa and Ribavirin. Hepatology. 38(1). 66–74. 77 indexed citations
17.
Ghany, Marc G., David E. Kleiner, Harvey J. Alter, et al.. (2003). Progression of fibrosis in chronic hepatitis C. Gastroenterology. 124(1). 97–104. 296 indexed citations
18.
Doo, Edward & T. Jake Liang. (2001). Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology. 120(4). 1000–1008. 72 indexed citations
19.
Lau, Daryl, Edward Doo, Marc G. Ghany, et al.. (2000). Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 32(4). 828–834. 288 indexed citations
20.
Lau, Daryl, Edward Doo, Yoon Park, et al.. (1999). Lamivudine for chronic delta hepatitis. Hepatology. 30(2). 546–549. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcello Persico Breakdown of academic impact, for papers by Bilal Hameed Breakdown of academic impact, for papers by Hari S. Conjeevaram Breakdown of academic impact, for papers by Lawrence Serfaty Breakdown of academic impact, for papers by Norberto C. Chávez‐Tapia Breakdown of academic impact, for papers by Yasuji Arase Breakdown of academic impact, for papers by Patrick Hillon Breakdown of academic impact, for papers by Andreas Geier Breakdown of academic impact, for papers by Naga Chalasani Breakdown of academic impact, for papers by Katsutoshi Tokushige
Rankless by CCL
2026